Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial

Jason Brunetta, Santiago Moreno Guillén, Andrea Antinori, Patrick Yeni, Barbara Wade, Margaret Johnson, Peter Shalit, Ramin Ebrahimi, Bethsheba Johnson, Ivan Walker, Shampa De-Oertel

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Patient-reported outcomes (PROs) can provide important information about treatment tolerability in HIV-1-infected patients. Objective: The aim of this study was to evaluate PROs following switching from a boosted protease inhibitor-based regimen to the single-tablet regimen (STR) of rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) in the 48-week open-label Switching Boosted PI to Rilpivirine in Combination with Truvada as a Single-Tablet Regimen (SPIRIT) trial. Methods: In the open-label SPIRIT trial, patients were randomized to receive an STR of RPV/FTC/TDF (n = 317) for 48 weeks or stay on their baseline regimen of a ritonavir-boosted protease inhibitor and two nucleoside/nucleotide analog reverse transcriptase inhibitors (PI + RTV + 2NRTIs, n = 159) for 24 weeks before switching to RPV/FTC/TDF for another 24 weeks. PRO assessments included the HIV Treatment Satisfaction Questionnaire (TSQ) and the HIV Symptom Index Questionnaire (SIQ). Results: At week 24, the mean HIV TSQ improvement from baseline was significantly greater in the RPV/FTC/TDF group than the PI + RTV + 2NRTIs group (p 

Original languageEnglish
Pages (from-to)257-267
Number of pages11
JournalPatient
Volume8
Issue number3
DOIs
Publication statusPublished - Mar 26 2015

ASJC Scopus subject areas

  • Nursing (miscellaneous)

Fingerprint Dive into the research topics of 'Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial'. Together they form a unique fingerprint.

Cite this